Bladder cancer
Stories
-
FDA approves durvalumab combination for cisplatin-ineligible muscle invasive bladder cancer
The FDA approved durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer in adults who are ineligible for or refused cisplatin-based chemotherapy. In VOLGA, the hazard ratio for event-free survival was 0.51 against radical cystectomy alone.